RxDoctor Payments DataLook up a doctor →

Bruce Hughes, MD

Neurology · Des Moines, IANPI 1285748004

Payments from drug & device makers

$2,117,507in general payments, 2019–2025

Across 1,609 payments — averaging $1316.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$528K
  • EMD Serono, Inc.$416K
  • E.r. Squibb & Sons, L.L.C.$200K
  • Genentech USA, Inc.$187K
  • Novartis$172K
  • Bristol Myers Squibb$126K
  • plus $489K from 20 others

What the payments were for

  • Consulting fees$253,02914%
  • Speaking & faculty fees$1,351,49974%
  • Travel & lodging$183,52010%
  • Food & beverage$38,7062%
  • Education$1,3230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,117,507 in reported general payments places this provider in the 95th percentile of 132 neurology providers in Iowa.

See all neurology providers in Iowa

Medicare billing

Part B allowed, 2024
$66,814
Medicare patients
422
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MavencladCladribine24$2,004,434
ZeposiaOzanimod Hydrochloride77$857,799
SolirisEculizumab14$850,391
VumerityDiroximel Fumarate52$452,024
MayzentSiponimod27$350,590
Kesimpta PenOfatumumab22$189,101
RebifInterferon Beta-1a/Albumin13$157,927
GilenyaFingolimod Hcl15$156,343
Gamunex-CImmune Globul G/Gly/Iga Avg 4634$116,268
TysabriNatalizumab11$89,849
Dalfampridine ErDalfampridine216$87,595
Teriflunomide46$86,580
GlatopaGlatiramer Acetate14$37,463
Glatiramer Acetate15$20,752
MyrbetriqMirabegron16$13,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Mavenclad, Rebif$415,833$2,162,36137 claims
E.r. Squibb & Sons, L.L.C.Zeposia$199,838$857,79977 claims
AstraZenecaSoliris$31,083$850,39114 claims
BiogenVumerity, Tysabri$527,978$541,87363 claims
NovartisMayzent, Gilenya$171,769$506,93342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 132 neurology providers in Iowa.

Other neurology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →